Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 2 » Issue 3

Religiosity in patients with Parkinson's disease

Authors Patrick McNamara, Raymon Durso, Ariel Brown

Published 15 September 2006 Volume 2006:2(3) Pages 341—348

Patrick McNamara, Raymon Durso, Ariel Brown

Department of Neurology, Boston University School of Medicine, Boston, MA, and VA Boston Healthcare System, Boston, MA, USA

Objective: To study clinical correlates of religiosity in Parkinson’s disease (PD).

Methods: Measures of life goals, religiosity, mood, and neuropsychologic function were assessed in 22 persons with mid-stage PD and 20 age-matched healthy controls. Levodopa dose equivalents (LDE) were also computed for the patients.

Results: Relative to other major life goals parkinsonian patients were significantly more likely to report that “my religion or life philosophy” was less important than were age-matched controls. Scores on a battery of religiosity scales were consistently lower for Parkinson’s patients than those of age-matched controls. While Mini Mental State Exam, logical memory recall, Stroop, and selected (depression and anxiety) mood scales reliably distinguished patients from controls, only measures of prefrontal function correlated with religiosity scores.

Conclusions: Patients with PD express less interest in religion and report consistently lower scores on measures of religiosity than age-matched controls. Prefrontal dopaminergic networks may support motivational aspects of religiosity.

Keywords: religiosity, Parkinson’s disease, neuropsychology, mood, executive functions, dopamine agonists

Download Article [PDF] 

Readers of this article also read:

Delivery of bone morphogenetic protein-2 and substance P using graphene oxide for bone regeneration

La WG, Jin M, Park S, Yoon HH, Jeong GJ, Bhang SH, Park H, Char K, Kim BS

International Journal of Nanomedicine 2014, 9:107-116

Published Date: 7 May 2014

Fullerene–biomolecule conjugates and their biomedicinal applications

Yang X, Ebrahimi A, Li J, Cui Q

International Journal of Nanomedicine 2014, 9:77-92

Published Date: 18 December 2013

The use of quartz crystal microbalance with dissipation (QCM-D) for studying nanoparticle-induced platelet aggregation

Santos-Martinez MJ, Inkielewicz-Stepniak I, Medina C, Rahme K, D'Arcy DM, Fox D, Holmes JD, Zhang H, Radomski MW

International Journal of Nanomedicine 2012, 7:243-255

Published Date: 13 January 2012

The evolving role of alemtuzumab (Campath-1H) in renal transplantation

Phuong-Thu T Pham, Gerald S Lipshutz, Phuong-Truc T Pham, Joseph Kawahji, Jennifer S Singer, Phuong-Chi T Pham

Drug Design, Development and Therapy 2009, 3:41-49

Published Date: 23 December 2008

Update on the use of pramipexole in the treatment of Parkinson’s disease

Radu Constantinescu

Neuropsychiatric Disease and Treatment 2008, 4:337-352

Published Date: 11 April 2008

Association between Randall’s plaque and calcifying nanoparticles

Neva Çiftçioglu, Kaveh Vejdani, Olivia Lee, Grace Mathew, Katja M Aho, et al

International Journal of Nanomedicine 2008, 3:105-115

Published Date: 7 March 2008

Review of frovatriptan in the treatment of migraine

Leslie Kelman

Neuropsychiatric Disease and Treatment 2008, 4:49-54

Published Date: 8 February 2008

Levetiracetam in the treatment of childhood epilepsy

James W Wheless

Neuropsychiatric Disease and Treatment 2007, 3:409-421

Published Date: 15 September 2007

Hypothesized predictors of patient—physician trust and distrust in the elderly: implications for health and disease management

Oswald AJ Mascarenhas, Lavoisier J Cardozo, Nelia M Afonso, Mohamed Siddique, Joel Steinberg, et al

Clinical Interventions in Aging 2006, 1:175-188

Published Date: 15 June 2006